We Develop Treatments For Chronic DiseasesSoin Neuroscience is a privately held, Ohio Based pharmaceutical company which is developing treatments for various chronic medical diseases using an oral formulation of sodium nitrite, licensed from TheraVasc, Inc. Initial studies were done on patients with poor blood flow to the extremities, such as those suffering from peripheral artery disease (PAD). In the U.S., 16 - 19 million people suffer from PAD but no effective treatments are currently available.
Learn more about us
TV1001SR is Being Developed to Treat Diabetic NeuropathyWe are developing a new drug, TV1001SR, to aid in the treatment of pain associated with diabetic neuropathy. With the incidence of diabetes steadily increasing and more people suffering from the symptoms of diabetic neuropathy, our research and development of this new drug may help reduce pain.
Learn About TV1001SR
TV1001SR and the Treatment of Peripheral Artery Disease (PAD)Peripheral artery disease (PAD) is a chronic disorder associated with reduced blood flow to the lower extremities affecting between 12-14 million people in the U.S. We are developing TV1001SR to help in the prevention and treatment of PAD in an effort to combat the affects of this disease.
Learn About TV1001SR
In the NewsOver the past several years, Theravasc has appeared in the news multiple times as we continue to work on the development of our new drug, TV1001SR. See press releases and news articles about us and the development of our new drug.
Breaking News From Soin Neuroscience
Watch the interview of Dr. Amol Soin on Fox 45 in Dayton as he explains our new experimental diabetic pain treatment.
Highland County Press Dr. Amol Soin, Medical Director of the Ohio Pain Clinic, with an office in Hillsboro, has announced the development of a treatment for diabetic neuropathy pain. Dr.
by Tristan Navera Dayton Business Journal - Febuary 4, 2015 Dr. Amol Soin is setting his sights on a new drug with immense potential for pain relief. It also has
Reach Out To Us
Learn more about our current treatments now.